Should all pregnant women be screened for hypothyroidism?
p r e g n a n cy. F u rt h e rm o r e , l ova s t atin can arrest cells in the G-1 phase of the cell cy c l e . 5 D i e t a ry intervention and the use of bile-acid sequestrants may not lower cholesterol c o n c e n t r ations sufficiently during pregnancy and may result in micronutrient inadequacy harmful to fetal gr ow t h . D i e t a ry manipulation may require supplementation with vitamins and minerals. All these measures may best be left until after the birt h . Equally important is the population or public-health approach to risk prevention in children and young adults before they themselves become parents. 6 D ata from the Bogalusa Heart Study and other p o p u l ations of children in the USA suggest a high p r e valence of obesity and of adve rse serum lipid concentrations and blood pressure values among children. T h e presence of a family history of heart disease, more than one risk factor for CHD in childhood, and adve rse behav i o u rs , such as excess dietary intake of calori e s , s at u r ated fat and c h o l e s t e r o l , cigarette smoking, and physical inactivity, a r e h a r b i n g e rs of the development of cardiovascular disease. C a r d i ovascular risk fa c t o rs do not occur as isolated eve n t s. They persist into adulthood, resulting in progr e s s i ve targetorgan damage from both atherosclerosis and hy p e rt e n s i o n , e ven in early life. Since unfavourable lifestyles and relat e d t r a i t s , such as raised blood pressure and serum lipids and early at h e r o s c l e r o s i s , are so prevalent among people in i n d u s t rialised countri e s , it is imperat i ve to examine all children and start prevention early in life.
The Finnish experience (STRIP Study) has shown that l owe ring of dietary fat in infa n cy does not harm gr ow t h d u ring the first 3 ye a rs of life.
7 Nor did the Dietary I n t e rvention Study in Children (DISC) show adve rs e effects of lowe ring of dietary fat on gr owth among p r e a d o l e s c e n t s. 8 In terms of drug therapy for fa m i l i a l hy p e r c h o l e s t e r o l a e m i a , a study of the efficacy and safety of l ova s t atin among adolescent boys with familial hy p e rcholesterolaemia showed no adve rse effects on gr owth and sexual development over the 48-week duration of the tri a l . It would be prudent to consider drug therapy for children at ve ry high risk of atherosclerosis after completion of pubert a l gr ow t h , especially for those with LDL cholesterol above 160 mg/dL (4·1 mmol/L) despite ri gid dietary treat m e n t and a positive family history of CHD and hy p e r c h o l e s t e r ol a e m i a .
Findings from the paediat ric studies cited above , complemented by necropsy dat a , 1 -3 s h ow clearly that ri s k fa c t o rs can be identified in childhood, and that dietary m a n i p u l ation to decrease intake of sat u r ated fat and cholesterol without undue restriction of calories has not interfered with gr ow t h . The increasing secular trends in o b e s i t y, the spread of cardiovascular disease wo r l d w i d e ,a n d the increasing prevalence of type 2 diabetes are compelling reasons for attempts to alter the natural course of atherosclerosis to start in childhood. Screening of all pregnant women for hy p o t hy r o i d i s m , preferably in the first tri m e s t e r , has been proposed by r e s e a r c h e rs whose large-scale retrospective study showe d t h at mild or subclinical mat e rnal hy p o t hyroidism duri n g p r e g n a n cy is associated with the child's poor perform a n c e on neuropsychological tests. The findings by James Haddow and colleagues 1 a r e i m p o rtant in emphasising the susceptibility of the d e veloping brain to thyroid disturbances during gestat i o n . There is evidence that the developing human brain needs t hyroid hormone from the first trimester of gestat i o n , 2 a n d until the fetal thyroid starts to produce thy r oxine in m i d g e s t at i o n , the fetus obtains its hormone entirely from the mother. M at e rnal serum concentrations of free t hy r oxine (FT4) at or below the tenth percentile at 12 we e k s ' g e s t ation (but not at 32 weeks) are associated with d e l ayed psychomotor development at age 10 months.
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3 T h i s f i n d i n g-t h at mat e rnal FT4 concentrations at the lowe r end of the normal range at the end of the first tri m e s t e r result in an insufficient placental transfer of t hy r ox i n e-i n d i c ates that the risk of impaired neurodeve lopment due to low exposure to the hormone is not confined to children of mothers with thyroid disease. H owe ve r , is there sufficient evidence that screening of pregnant women for thyroid function, f o l l owed by t r e atment of those with mild hy p o t hy r o i d i s m , will prov i d e wo rthwhile benefit to the children? 1 , 4 In Haddow and colleagues' s t u d y, 15 tests relating to i n t e l l i g e n c e , at t e n t i o n , school perform a n c e , and visual motor skills were gi ven to 62 children aged 7-9 ye a rs whose m o t h e rs ' s e rum collected during pregnancy indicat e d hy p o t hy r o i d i s m . There was a significant 4-point difference b e t ween the groups in mean IQ, but this difference represents only a small effect size.
5 More important than the overall group difference, t h o u g h , is whether there is a difference in proportions of children with low IQ scores. I n the general populat i o n , about 16% of children have IQs t h at are more than 1 SD (15 points) below the mean (ie, IQs lower than 85).
3 A similar percentage (15%) was found among the children of the hy p o t hyroid women in Haddow and colleagues' study so, although this proportion is significantly gr e ater than the 5% found among the controls, the difference might be due to high performance among the controls rather than poor functioning among the cases.
Another point to consider is that the effects of thy r ox i n e d e f i c i e n cy or thy r oxine supplementation may differ for va rious neurodevelopmental feat u r e s. For example, H a d d ow and colleagues' findings indicate that attention is a d ve rsely affected among children of women treated for hy p o t hy r o i d i s m .
1 In another study, 6 c o g n i t i ve deve l o p m e n t was appropri ate among children with congenital hy p ot hyroidism gi ven thy r oxine supplements early, but when the children were examined according to horm o n e c o n c e n t r at i o n s , attention deficits and subtle motor problems were commoner among those with the highest FT4 concentrat i o n s , although these concentrations we r e within the normal range. 4 Such findings suggest that t r e atment with thy r oxine might not be free of adve rs e e f f e c t s , and this point must be clarified before a decision to screen is taken.
Once the benefit of screening is decided upon, i t s practicability and its sensitivity and specificity should also be considered, as the Endocrine Society plans to do. Fo r i n s t a n c e , w h at va riable should be used for the screening? Should it be thy r o t r o p i n , F T 4 , or thyroid perox i d a s e antibody (TPO-Ab)? Generally, the detection of thy r o i d dysfunction is based initially on thyrotropin concentrat i o n , and the society has recommended that for now this h o rmone should be measured for women with personal or family history of thyroid disease or symptoms suggestive of hy p o t hy r o i d i s m . But how accurate is thyrotropin as an index of mat e rnal FT4 concentrations or of adequacy of t hy r oxine transfer to the fetus? Low concentrations of m at e rnal serum FT4 have been associated with norm a l t hyrotropin concentrations during pregnancy, and this p at t e rn has been termed gestational hy p o t hy r ox i n a e m i a , a s t ate in which the " t hy r oxine env i r o n m e n t " is inappropri at e for the fetus rather than for the mother.
7 If FT4 is the va riable to be used in screening, w h at cut-off value should be used to define gestational hy p o t hy r oxinaemia? Inform e d choice would require knowledge of the frequency d i s t ri bution of FT4 concentrations in iodine-replete wo m e n (probably for each trimester of pregnancy ) . 7 The predictive p ower of TPO-Ab is too low for use in screening, e ve n though women with these antibodies are at increased risk of h aving FT4 concentrations at the low end of the norm a l range at 12 we e k s 'g e s t at i o n .
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The next question to consider is when the woman should be screened. The first antenatal visit, e ven if it is in the firs t t ri m e s t e r , might be too lat e . The logistics of preconception screening are enorm o u s. B e s i d e s , the relation betwe e n m at e rnal FT4 concentrations before pregnancy and those d u ring early pregnancy is not know n .
F i n a l l y, h ow should the mother be treated? The relat i o n b e t ween low mat e rnal FT4 and impairment of the child's n e u r o d e velopment has not been proven to be causal. T h e recent identification of metabolic pat h ways other than transplacental diffusion invo l ved in mat e rnal-fetal transfer of FT4 8 might mean that low concentrations of mat e rn a l t hyroid hormone only indirectly impair the supply of t hyroid hormone to the fetus. The possibility that children at risk would benefit from treatment of the mother with t hy r oxine should be confirmed by a placebo-controlled tri a l of adequate statistical powe r , after the dose and the d u r ation of supplementation of thy r oxine have been studied in gr e ater detail. F i n a l l y, is there an altern at i ve to screening followed by therapy? As pointed out in the commentary accompany i n g
increased during pregnancy, should not be f o r g o t t e n . Such measures are easier to implement than screening of thyroid function during or before pregnancy, and will benefit the general populat i o n . The past few ye a rs have seen a striking expansion in k n owledge about the signals and switches invo l ved in cellular immunity. CD40 has emerged as a part i c u l a r l y i m p o rtant molecule, and its central role is starting to be exploited in studies of immunotherapy for tumours in human beings. Three recent papers 1 -3 suggest that antibodies to CD40 can stimulate (not block) CD40 and p r ovoke immunity to tumours in mice.
CD40 induces immunity through activation and expansion of dendritic cells, B cells, and T cells. CD40 was ori ginally identified as an activator of B-lymphocy t e p r o l i f e r ation and is a transmembrane protein of the fa m i l y of tumour-necrosis-factor receptors. Interaction betwe e n CD40 on dendritic cells and the CD40 ligand (CD40L, n ow designated CD154) on naïve CD4-positive T-h e l p e r cells plays a crucial role at the start of the immune r e s p o n s e , in which the T-helper cells undergo activat i o n and the dendritic cells mat u r e . Signalling through CD40 on dendritic cells enables them to present antigen more e f f e c t i ve l y, through expression of costimulat o ry molecules and the production of interleukin-12, which in turn produces further T-cell stimulat i o n . The activated T-h e l p e r cells can then signal to B cells via CD40, 4 so that CD40-a c t i vated B cells also develop a potent antigen-presenting f u n c t i o n .
5 C D 4 0 -a c t i vated antigen-presenting cells can in their turn stimulate CD8-positive cy t o t oxic T cells. 6 , 7 These interactions explain how rare T-helper and cy t o t ox i c T cells with receptors specific for a particular antigen (eg, a tumour antigen) can both be stimulated by the same antigen-presenting cell without all three being present s i m u l t a n e o u s l y. A c t i vated T-helper cells can stimulat e
